Infection Risk After Orthopaedic Surgery in Patients with Inflammatory Rheumatic Diseases, with Focus On Discontinuation of TNF-Alpha-Inhibitors

被引：0
|
作者：
Scherrer, Catrina B. [1 ]
Mannion, Anne A. F. [1 ]
Kyburz, Diego [2 ]
Vogt, Markus [3 ]
Kramers-de Quervain, Ines A. [1 ]
机构：
[1] Schulthess Clin, Zurich, Switzerland
[2] Ctr Exp Rheumatol, Zurich, Switzerland
[3] Cantonal Hosp Zug, Baar, Switzerland
来源：
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1669
引用
收藏
页码：S713 / S714
页数：2
相关论文
共 50 条
  • [31] Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs)
    de Boer, Merel
    Gosselt, Helen R.
    Jansen, Jurriaan
    van Doorn, Martijn B. A.
    Hoentjen, Frank
    Nurmohamed, Michael T.
    Spuls, Phyllis, I
    Tas, Sander W.
    Vonkeman, Harald E.
    Jessurun, Naomi T.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2023, 22 (03) : 195 - 202
  • [32] SECOND LINE TREATMENT PERSISTENCE AND COSTS AMONG PATIENTS WITH IMMUNE-MEDIATED RHEUMATIC DISEASES TREATED WITH SUBCUTANEOUS TNF-ALPHA INHIBITORS
    Dalen, J.
    Svedbom, A.
    Black, C. M.
    Kachroo, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 447 - 447
  • [33] Serious Infection Risk in Patients with Rheumatoid Arthritis Compared to Patients with Non-Inflammatory Rheumatic Diseases: A US National Cohort Study
    Mehta, Bella Y.
    Pedro, Sofia
    Ozen, Gulsen
    Michaud, Kaleb
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [34] Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study
    Roest, Lieke H.
    Kosse, Leanne J.
    van Lint, Jette A.
    Gosselt, Helen R.
    Scholl, Joep H. G.
    van Puijenbroek, Eugene
    Vonkeman, Harald E.
    Tas, Sander W.
    Nurmohamed, Michael T.
    van den Bemt, Bart J. F.
    Jessurun, Naomi T.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2023, 22 (03) : 203 - 211
  • [35] Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors
    Johan Dalén
    Axel Svedbom
    Christopher M. Black
    Sumesh Kachroo
    [J]. Rheumatology International, 2017, 37 : 2049 - 2058
  • [36] Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors
    Dalen, Johan
    Svedbom, Axel
    Black, Christopher M.
    Kachroo, Sumesh
    [J]. RHEUMATOLOGY INTERNATIONAL, 2017, 37 (12) : 2049 - 2058
  • [37] AFTER SURGERY WITH PROSTHESIS THE INFECTION RATES IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED BY TNF ALPHA BLOCKADE COMPARED TO CONVENTIONAL NSAIDS
    Lee, S. H.
    Hong, S. J.
    Chung, S. W.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (05) : 811 - 811
  • [38] Impact of Non-Persistence on Healthcare Resource Utilization and Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study
    Carballo, Nuria
    Garcia-Alzorriz, Enric
    Ferrandez, Olivia
    Navarrete-Rouco, Maria Eugenia
    Duran-Jorda, Xavier
    Perez-Garcia, Carolina
    Monfort, Jordi
    Cots, Francesc
    Grau, Santiago
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [39] Risk of hepatitis B virus reactivation in patients treated with anti-TNF alpha agents for immune-mediated inflammatory diseases
    Pereira, R.
    Raposo, I.
    Nery, F.
    Torres, T.
    [J]. ACTAS DERMO-SIFILIOGRAFICAS, 2018, 109 (03): : 286 - 289
  • [40] Risk of Herpes Viruses Infections (HSV, VZV) During Anti-TNF Therapy in Patients With Inflammatory Rheumatic Diseases Systematic Review and Meta-Analysis.
    Che, Helene
    Morel, Jacques
    Combe, Bernard G.
    Lukas, Cedric
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S169 - S169
12345